Tempest Therapeutics Inc

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.